US68622V1061
© BusinessWire
17.01.2026
OGN
LISTED
NYSE
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
News Preview
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON® (etonogestrel implant), which is indicated for use by women of reproductive pot...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2026
OGN
LISTED
NYSE
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
News Preview
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for pa...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2025
OGN
LISTED
NYSE
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
News Preview
Organon (NYSE: OGN), announced today that Joe Morrissey, Interim Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd, 2025 at 10:00 a.m. ET.
Investors, analysts, members of the media and the general pu...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
17.11.2025
OGN
LISTED
NYSE
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
News Preview
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
15.11.2025
OGN
LISTED
NYSE
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Organon & Co. (NYSE: OGN). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
OGN
LISTED
NYSE
Organon Reports Results for the Third Quarter Ended September 30, 2025
News Preview
Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025.
“I am humbled to be working alongside our talented team during this pivotal time for Organon,” said Joe Morrissey, Organon’s Interim Chief Executive Officer. “We are harnessing the company's many strengths, including a diverse portfolio that we expect...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
OGN
LISTED
NYSE
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
News Preview
Organon (NYSE: OGN), a global independent healthcare company with a focus on women’s health, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orla...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
OGN
LISTED
NYSE
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
News Preview
Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
OGN
LISTED
NYSE
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
News Preview
Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET.
The webcast and conference call will be hosted by Carrie Cox, Organon’s Executive Board Chair; Joe Morri...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
OGN
LISTED
NYSE
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Organon & Co. (NYSE: OGN). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com...
Themefolio
Profiler
Peergroup
© BusinessWire
27.10.2025
OGN
LISTED
NYSE
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation
News Preview
Organon (NYSE: OGN) (“Organon” or “the company”) today announced that its Board of Directors has appointed the Company’s Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair t...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
OGN
LISTED
NYSE
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
News Preview
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the referenc...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
02.09.2025
OGN
LISTED
NYSE
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
News Preview
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference pr...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
OGN
LISTED
NYSE
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) and reminds investors of the July 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Fa...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
OGN
LISTED
NYSE
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025
News Preview
Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its second quarter 2025 financial results on August 5, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
Accessing Second Quarter 2025 Financial Results Webcast
Interested parties may access the live call vi...
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
OGN
LISTED
NYSE
Deadline Soon: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming July 22, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between November 3, 2022 to April 30, 2025, inclusive (the “Class P...
Themefolio
Profiler
Peergroup
© BusinessWire
19.07.2025
OGN
LISTED
NYSE
ORGANON 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Organon & Co. - OGN
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in securities class action lawsuits against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between November 3, 2022 an...
Themefolio
Profiler
Peergroup
© BusinessWire
09.07.2025
OGN
LISTED
NYSE
EXTENDED CLASS PERIOD: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Organon & Co. and Announces Opportunity for Investors with Substantial Losses to Lead the Organon Class Action Lawsuit – OGN
News Preview
Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. (NYSE: OGN) publicly traded securities between November 3, 2022 and April 30, 2025, inclusive (the “Class Period”). Captioned Lerner v. Organon & Co., No. 25-cv-12983 (D.N.J.), the Organon class action la...
Themefolio
Profiler
Peergroup
© BusinessWire
07.07.2025
OGN
LISTED
NYSE
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis
News Preview
Organon (NYSE: OGN), a global independent healthcare company with a focus on women’s health, today announced that VTAMA® (tapinarof) cream, 1%, was granted a strong recommendation by the American Academy of Dermatology (AAD) in their 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis (AD). The reco...
Themefolio
Profiler
Peergroup
© BusinessWire
02.07.2025
OGN
LISTED
NYSE
Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain
News Preview
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in endometriosis-related pain did not meet its primary efficacy endpoint. OG-6219 is an oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor, whi...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
OGN
LISTED
NYSE
Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Period”...
Themefolio
Profiler
Peergroup
© BusinessWire
04.06.2025
OGN
LISTED
NYSE
Deadline Approaching: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR WHO...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
OGN
LISTED
NYSE
Law Offices of Frank R. Cruz Encourages Organon & Co. (OGN) Investors to Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Period”). Organon investors have until July 22, 2025 to file a lead plaintiff motion.
IF...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
OGN
LISTED
NYSE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Organon & Co. (OGN) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Per...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
OGN
LISTED
NYSE
Law Offices of Howard G. Smith Encourages Organon & Co. (OGN) Investors To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Period”). Organon investors have until July 22, 2025 to file a lead plaintiff motion.
IF Y...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
OGN
LISTED
NYSE
Securities Fraud Investigation Into Organon & Co. (OGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON ORGANON &am...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
OGN
LISTED
NYSE
Organon & Co. (OGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ORGANON & CO. (OGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PU...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
OGN
LISTED
NYSE
OGN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon and certain of Organon’s executives with violations of the Securities Exc...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
OGN
LISTED
NYSE
Securities Fraud Investigation Into Organon & Co. (OGN) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON ORGANON & CO. (OGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO REC...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
OGN
LISTED
NYSE
Rosen Law Firm Urges Organon & Co. (NYSE: OGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, 2025, both dates inclusive (the “Class Period”). Organon is a healthcare company.
For more information, submit a form, email attorn...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
OGN
LISTED
NYSE
OGN BREAKING NEWS: Organon & Co. Stock Plummets 27% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NYSE:OGN)
News Preview
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws.
If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfa...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
OGN
LISTED
NYSE
Rosen Law Firm Encourages Organon & Co. Investors to Inquire About Securities Class Action Investigation – OGN
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Organon & Co. (NYSE: OGN) resulting from allegations that Organon may have issued materially misleading business information to the investing public.
So What: If you purchased Organon securities you m...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
OGN
LISTED
NYSE
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
News Preview
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira® (adalimumab).2 These inter...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
OGN
LISTED
NYSE
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organon & Co. (“Organon” or “the Company”) (NYSE: OGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investo...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
OGN
LISTED
NYSE
ORGANON SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between October 31, 2024 and A...
Themefolio
Profiler
Peergroup
© BusinessWire
26.05.2025
OGN
LISTED
NYSE
OGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon as well as certain of Organon’s executives with violations of the Securit...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
OGN
LISTED
NYSE
OGN INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Organon & Co. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
If you have info...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
OGN
LISTED
NYSE
Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. (“Organon” or “the Company”) (NYSE: OGN) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. A...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
OGN
LISTED
NYSE
OGN Investors Have Opportunity to Join Organon & Co. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Organon & Co. (“Organon” or “the Company”) (NYSE: OGN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclo...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
OGN
LISTED
NYSE
Organon Reports Results for the First Quarter Ended March 31, 2025
News Preview
Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2025.
“We have reset our capital allocation priorities to accelerate progress towards deleveraging, enabling a path to achieve a net leverage ratio of below 4.0x by year-end. Over the last year, we have established a leaner, more fit-for-purpose cost structure w...
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
OGN
LISTED
NYSE
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
News Preview
Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon’s Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board’s Talent Committee. In connection with Ms....
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
OGN
LISTED
NYSE
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
News Preview
Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
IPR&D and Milestones
Organon currently expects that it will record approximately $6 million of milestone...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
OGN
LISTED
NYSE
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
News Preview
Organon (NYSE: OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (Nasdaq: BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market,...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
OGN
LISTED
NYSE
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
News Preview
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and ch...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
OGN
LISTED
NYSE
MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO
News Preview
Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility
PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical devi...
Themefolio
Profiler
Peergroup
© BusinessWire
08.03.2025
OGN
LISTED
NYSE
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
News Preview
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA® (tapinarof) cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD), also known as eczema. The findings d...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
OGN
LISTED
NYSE
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
News Preview
Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024.
“In 2024 we achieved our third year of constant currency revenue growth and delivered Adjusted EBITDA margin expansion ex-IPR&D,” said Kevin Ali, Organon's chief executive officer. “Our 2025 financial guidance reflects the potential...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
OGN
LISTED
NYSE
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
News Preview
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its fourth quarter and full year 2024 financial results on February 13, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
IPR&D and Milestones
Organon does not currently expect to record any milestone expense in...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
OGN
LISTED
NYSE
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, 2025, at 3:45 p.m. PT.
Investors, analysts, members of the media and the general public are invited...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
OGN
LISTED
NYSE
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
News Preview
Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in a...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
OGN
LISTED
NYSE
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
News Preview
Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months the target action date of its review of the supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) cream, 1% as a treatment for ato...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
OGN
LISTED
NYSE
Organon Reports Results for the Third Quarter Ended September 30, 2024
News Preview
Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2024.
"In 2024 our commercial execution has been very strong. Our largest product, Nexplanon, is well positioned to deliver $1 billion of revenue next year and we've added other notable growth drivers with Emgality and most recently, VTAMA," said Kevin Ali,...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
OGN
LISTED
NYSE
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
News Preview
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for HLX14, an investigational biosimilar of PROLIA/XGEVA (denosumab).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/hom...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
OGN
LISTED
NYSE
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
News Preview
Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-der...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
OGN
LISTED
NYSE
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
News Preview
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
IPR&D and Milestones
Organon currently expects that it will record $51 million of milestone expense in the...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2024
OGN
LISTED
NYSE
Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands
News Preview
Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women's health.
KIRKLAND, QC, Oct. 8, 2024 /CNW/ - Organon Cana...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2024
OGN
LISTED
NYSE
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
News Preview
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candid...
Themefolio
Profiler
Peergroup
© PR Newswire
26.09.2024
OGN
LISTED
NYSE
Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada
News Preview
This World Contraception Day, organizations partner to raise awareness of the need to reduce barriers to contraception and invite others to support universal access
KIRKLAND, QC and EDMONTON, AB, Sept. 26, 2024 /CNW/ - In recognition of World Contraception Day (WCD) on September 26, Organon Canada, a subsidiary of Organon (NYSE: OGN), a globa...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2024
OGN
LISTED
NYSE
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
News Preview
Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant (NASDAQ: ROIV) company dedicated to developing and commercializing innovative th...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2024
OGN
LISTED
NYSE
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
News Preview
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced it has expanded its agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine medicine Emgality® (galcanezumab) in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar,...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
